# HNF1A

## Overview
HNF1A is a gene that encodes the transcription factor HNF1 homeobox A, which plays a pivotal role in the regulation of gene expression in various tissues, including the liver and pancreatic islets. The HNF1A protein is characterized by a dimerization domain, a DNA-binding domain, and a transactivation domain, each contributing to its function in cellular metabolism and gene regulation. This protein is involved in critical metabolic pathways, influencing processes such as glycolysis, gluconeogenesis, and insulin secretion. Mutations in the HNF1A gene are associated with several clinical conditions, most notably maturity-onset diabetes of the young type 3 (MODY3). The protein's interactions with other cellular molecules underscore its importance in maintaining metabolic balance and responding to physiological changes (Kind2021Structural; Harries2006Isomers; Servitja2009Hnf1α).

## Structure
The HNF1A protein, encoded by the HNF1A gene, exhibits a complex molecular structure integral to its function as a transcription factor. The protein is composed of several distinct domains: an N-terminal dimerization domain, a central DNA-binding domain, and a C-terminal transactivation domain. 

The N-terminal dimerization domain spans the first 32 amino acids and is crucial for the formation of homodimers or heterodimers, essential for the protein's transcriptional activity (Kind2021Structural; Yang1999Structure/Function). This domain forms a four-helix bundle that facilitates homodimerization (Valkovicova2019Novel).

The DNA-binding domain is bipartite, consisting of a Pit-Oct-Unc-specific (POUS) domain and a homeodomain (POUH), which together form a helix-turn-helix structure. This domain binds to the inverted palindromic consensus DNA sequence 5'-GTTAATNATTAAC-3' (Kind2021Structural; Çubuk2021A).

The C-terminal transactivation domain, spanning amino acids 282 to 631, is involved in gene transcription activation and interacts with various transcription factors, co-activators, and repressors (Kind2021Structural).

Additionally, HNF1A exists in three transcriptional isoforms (A, B, and C) generated by alternative splicing, which show tissue-specific expression and varying transcriptional activities (Valkovicova2019Novel). These isoforms differ in the length of the C-terminal transactivation domain and their expression in fetal and adult tissues (Kind2021Structural).

## Function
HNF1A (Hepatocyte Nuclear Factor 1 Alpha) is a transcription factor that plays a critical role in the regulation of gene expression in various tissues, particularly in the liver and pancreatic islets. In the liver, HNF1A influences the expression of genes involved in metabolic processes such as glycolysis, gluconeogenesis, and lipid metabolism (Servitja2009Hnf1α). It also regulates genes linked to bile acid and cholesterol metabolism, highlighting its role in maintaining metabolic balance (Servitja2009Hnf1α).

In pancreatic β cells, HNF1A is essential for the normal function of these cells by regulating genes critical for insulin secretion and β-cell growth. It controls the expression of the GLUT2 gene, crucial for glucose uptake and ATP production, and mutations in HNF1A can severely impair glucose uptake and disrupt ATP production, contributing to diabetes (Low2021Decreased). The protein's activity affects both the upregulation and downregulation of genes, depending on the tissue type and the specific metabolic pathways involved (Servitja2009Hnf1α).

Furthermore, HNF1A plays a significant role in the transcriptional networks that govern embryonic pancreas development and differentiation, as well as in maintaining the growth and function of islet β cells in adults (Luo2015Hepatocyte). Its involvement in these processes is crucial for the proper development and function of the endocrine pancreas, impacting overall metabolic health.

## Clinical Significance
Mutations in the HNF1A gene are primarily associated with maturity-onset diabetes of the young type 3 (MODY3), a form of monogenic diabetes characterized by autosomal dominant inheritance and early onset, typically before 25 years of age. These mutations lead to pancreatic beta-cell dysfunction, resulting in an inability to adequately increase insulin secretion in response to hyperglycemia (Harries2006Isomers; Ellard2006Mutations). The clinical expression of MODY3 is highly variable, influenced by both genetic and environmental factors, and the type and location of mutations significantly affect the age at diagnosis (Bellanné-Chantelot2008The).

In addition to diabetes, mutations in HNF1A have been linked to hepatic adenomas and hepatocellular carcinoma (HCC). Bi-allelic mutations in HNF1A are associated with a significant loss of function, suggesting a role as a tumor-suppressor gene in liver carcinogenesis (Bluteau2002Bi-allelic). Furthermore, the presence of germline mutations in HNF1A in individuals with familial diabetes and liver tumors indicates a genetic predisposition to benign liver tumor development linked to diabetes mellitus (Bluteau2002Bi-allelic).

The identification of an HNF1A mutation in a diabetic patient not only confirms a diagnosis of MODY but also assists in predicting the clinical course and prognosis. Patients with HNF1A mutations typically show a better response to sulfonylurea drugs compared to metformin, influencing treatment decisions (Ellard2006Mutations).

## Interactions
HNF1A interacts with various proteins and nucleic acids, playing a crucial role in gene regulation and cellular functions. One significant interaction is with CBP/p300 acetyltransferases, which are essential for the transcriptional activation function of HNF1A. TGFβ treatment impairs this interaction by altering the post-translational modification profile of HNF1A, reducing its ability to recruit these acetyltransferases to target gene promoters (Bisceglia2019TGFβ).

Additionally, HNF1A interacts with KPNA proteins, specifically KPNA2, KPNA4, and KPNA6. These interactions involve hydrophobic pockets and hydrogen bonding, with KPNA6 showing the highest binding affinity, which is crucial for the nuclear localization and function of HNF1A (Fareed2021HNF1A-MODY).

HNF1A also interacts with the E3 SUMO ligase PIASγ, which regulates its activity by affecting its transcriptional activity and possibly its stability. This interaction does not depend on SUMOylation at specific lysine residues, indicating a SUMOylation-independent regulatory mechanism by PIASγ (Kaci2018The).

These interactions highlight the complex regulatory mechanisms of HNF1A, involving both stable and transient protein-protein interactions, crucial for its role in cellular metabolism and gene expression regulation.


## References


[1. (Valkovicova2019Novel) Terezia Valkovicova, Martina Skopkova, Juraj Stanik, and Daniela Gasperikova. Novel insights into genetics and clinics of the hnf1a-mody. Endocrine Regulations, 53(2):110–134, April 2019. URL: http://dx.doi.org/10.2478/enr-2019-0013, doi:10.2478/enr-2019-0013. (88 citations) 10.2478/enr-2019-0013](https://doi.org/10.2478/enr-2019-0013)

[2. (Bluteau2002Bi-allelic) Olivier Bluteau, Emmanuelle Jeannot, Paulette Bioulac-Sage, Juan Martin Marqués, Jean-Frédéric Blanc, Hung Bui, Jean-Christophe Beaudoin, Dominique Franco, Charles Balabaud, Pierre Laurent-Puig, and Jessica Zucman-Rossi. Bi-allelic inactivation of tcf1 in hepatic adenomas. Nature Genetics, 32(2):312–315, September 2002. URL: http://dx.doi.org/10.1038/ng1001, doi:10.1038/ng1001. (283 citations) 10.1038/ng1001](https://doi.org/10.1038/ng1001)

[3. (Yang1999Structure/Function) Qin Yang, Kazuya Yamagata, Koji Yamamoto, Jun-ichiro Miyagawa, Jun Takeda, Naoko Iwasaki, Hiromi Iwahashi, Issei Yoshiuchi, Mitsuyoshi Namba, Jun-ichi Miyazaki, Toshiaki Hanafusa, and Yuji Matsuzawa. Structure/function studies of hepatocyte nuclear factor-1α, a diabetes-associated transcription factor. Biochemical and Biophysical Research Communications, 266(1):196–202, December 1999. URL: http://dx.doi.org/10.1006/bbrc.1999.1747, doi:10.1006/bbrc.1999.1747. (29 citations) 10.1006/bbrc.1999.1747](https://doi.org/10.1006/bbrc.1999.1747)

[4. (Low2021Decreased) Blaise Su Jun Low, Chang Siang Lim, Shirley Suet Lee Ding, Yaw Sing Tan, Natasha Hui Jin Ng, Vidhya Gomathi Krishnan, Su Fen Ang, Claire Wen Ying Neo, Chandra S. Verma, Shawn Hoon, Su Chi Lim, E. Shyong Tai, and Adrian Kee Keong Teo. Decreased glut2 and glucose uptake contribute to insulin secretion defects in mody3/hnf1a hipsc-derived mutant β cells. Nature Communications, May 2021. URL: http://dx.doi.org/10.1038/s41467-021-22843-4, doi:10.1038/s41467-021-22843-4. (39 citations) 10.1038/s41467-021-22843-4](https://doi.org/10.1038/s41467-021-22843-4)

[5. (Kaci2018The) Alba Kaci, Magdalena Keindl, Marie H. Solheim, Pål R. Njølstad, Lise Bjørkhaug, and Ingvild Aukrust. The e3 sumo ligase piasγ is a novel interaction partner regulating the activity of diabetes associated hepatocyte nuclear factor-1α. Scientific Reports, August 2018. URL: http://dx.doi.org/10.1038/s41598-018-29448-w, doi:10.1038/s41598-018-29448-w. (15 citations) 10.1038/s41598-018-29448-w](https://doi.org/10.1038/s41598-018-29448-w)

[6. (Çubuk2021A) Hasan Çubuk and Özlem Yalçın Çapan. A review of functional characterization of single amino acid change mutations in hnf transcription factors in mody pathogenesis. The Protein Journal, 40(3):348–360, May 2021. URL: http://dx.doi.org/10.1007/s10930-021-09991-8, doi:10.1007/s10930-021-09991-8. (10 citations) 10.1007/s10930-021-09991-8](https://doi.org/10.1007/s10930-021-09991-8)

[7. (Harries2006Isomers) Lorna W. Harries, Sian Ellard, Amanda Stride, Noel G. Morgan, and Andrew T. Hattersley. Isomers of the tcf1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. Human Molecular Genetics, 15(14):2216–2224, June 2006. URL: http://dx.doi.org/10.1093/hmg/ddl147, doi:10.1093/hmg/ddl147. (97 citations) 10.1093/hmg/ddl147](https://doi.org/10.1093/hmg/ddl147)

[8. (Ellard2006Mutations) Sian Ellard and Kevin Colclough. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (hnf1a) and 4 alpha (hnf4a) in maturity-onset diabetes of the young. Human Mutation, 27(9):854–869, September 2006. URL: http://dx.doi.org/10.1002/humu.20357, doi:10.1002/humu.20357. (140 citations) 10.1002/humu.20357](https://doi.org/10.1002/humu.20357)

[9. (Kind2021Structural) Structural and biophysical characterization of HNF-1A as a tool to study MODY3 diabetes variants (0 citations) 10.1101/2021.12.20.473529](https://doi.org/10.1101/2021.12.20.473529)

[10. (Fareed2021HNF1A-MODY) Fareed M. A. Fareed, Sirin Korulu, Mehmet Özbil, and Özlem Yalçın Çapan. Hnf1a-mody mutations in nuclear localization signal impair hnf1a-import receptor kpna6 interactions. The Protein Journal, 40(4):512–521, January 2021. URL: http://dx.doi.org/10.1007/s10930-020-09959-0, doi:10.1007/s10930-020-09959-0. (1 citations) 10.1007/s10930-020-09959-0](https://doi.org/10.1007/s10930-020-09959-0)

[11. (Luo2015Hepatocyte) Zhaofan Luo, Yanan Li, Huamin Wang, Jason Fleming, Min Li, Yaan Kang, Ran Zhang, and Donghui Li. Hepatocyte nuclear factor 1a (hnf1a) as a possible tumor suppressor in pancreatic cancer. PLOS ONE, 10(3):e0121082, March 2015. URL: http://dx.doi.org/10.1371/journal.pone.0121082, doi:10.1371/journal.pone.0121082. (70 citations) 10.1371/journal.pone.0121082](https://doi.org/10.1371/journal.pone.0121082)

[12. (Bisceglia2019TGFβ) Francesca Bisceglia, Cecilia Battistelli, Valeria Noce, Claudia Montaldo, Agatino Zammataro, Raffaele Strippoli, Marco Tripodi, Laura Amicone, and Alessandra Marchetti. Tgfβ impairs hnf1α functional activity in epithelial-to-mesenchymal transition interfering with the recruitment of cbp/p300 acetyltransferases. Frontiers in Pharmacology, August 2019. URL: http://dx.doi.org/10.3389/fphar.2019.00942, doi:10.3389/fphar.2019.00942. (8 citations) 10.3389/fphar.2019.00942](https://doi.org/10.3389/fphar.2019.00942)

[13. (Servitja2009Hnf1α) Joan-Marc Servitja, Miguel Pignatelli, Miguel Ángel Maestro, Carina Cardalda, Sylvia F. Boj, Juanjo Lozano, Enrique Blanco, Amàlia Lafuente, Mark I. McCarthy, Lauro Sumoy, Roderic Guigó, and Jorge Ferrer. Hnf1α (mody3) controls tissue-specific transcriptional programs and exerts opposed effects on cell growth in pancreatic islets and liver. Molecular and Cellular Biology, 29(11):2945–2959, June 2009. URL: http://dx.doi.org/10.1128/mcb.01389-08, doi:10.1128/mcb.01389-08. (108 citations) 10.1128/mcb.01389-08](https://doi.org/10.1128/mcb.01389-08)

[14. (Bellanné-Chantelot2008The) Christine Bellanné-Chantelot, Claire Carette, Jean-Pierre Riveline, René Valéro, Jean-François Gautier, Etienne Larger, Yves Reznik, Pierre-Henri Ducluzeau, Agnès Sola, Agnès Hartemann-Heurtier, Pierre Lecomte, Lucy Chaillous, Marie Laloi-Michelin, Jean-Marie Wilhem, Pierre Cuny, Françoise Duron, Bruno Guerci, Nathalie Jeandidier, Helen Mosnier-Pudar, Michel Assayag, Danièle Dubois-Laforgue, Gilberto Velho, and José Timsit. The type and the position of hnf1a mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (mody)-3. Diabetes, 57(2):503–508, February 2008. URL: http://dx.doi.org/10.2337/db07-0859, doi:10.2337/db07-0859. (153 citations) 10.2337/db07-0859](https://doi.org/10.2337/db07-0859)